Verve Therapeutics
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve Therapeutics has raised €56M across 1 funding round from 1 investor, most recently a Series A round in Jun 2020. Based in Cambridge, United States; founded 2018; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€56M
€56,000,000
Funding rounds
1
Investors
1
distinct backers
Active since
2020-06
latest 2020-06
Funding by year
EUR raised per yearVerve Therapeutics — funding by year — interactive chart.
Data table
| Verve Therapeutics — funding by year | |
|---|---|
| 2020 | €56M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-06-16 | Series A | €56M | GV | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData